ketoconazole has been researched along with Benign Neoplasms in 69 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rivaroxaban is a viable anticoagulant for the management of cancer-associated venous thromboembolism (CA-VTE)." | 8.12 | Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism. ( Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z, 2022) |
| "Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen." | 7.68 | Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992) |
| " Treatment of invasive aspergillosis required a higher dosage (about 5 mg/kg) and prolonged administration." | 5.28 | Experience with itraconazole in cryptococcosis and aspergillosis. ( Almaviva, M; Cristina, S; De Maria, R; Ferrazzi, P; Fiocchi, R; Langer, M; Negri, C; Scoccia, S; Tortorano, AM; Viviani, MA, 1989) |
| "Rivaroxaban is a viable anticoagulant for the management of cancer-associated venous thromboembolism (CA-VTE)." | 4.12 | Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism. ( Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z, 2022) |
| "Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen." | 3.68 | Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992) |
| " Eighty-eight patients were enrolled across the 3 drug-drug interaction studies; the ixazomib toxicity profile was consistent with previous studies." | 2.87 | Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana ( Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X, 2018) |
| " Overall, the safety profile of romidepsin was not altered by coadministration with ketoconazole or rifampin, except that a higher incidence and greater severity of thrombocytopenia was observed when romidepsin was given with rifampin." | 2.80 | Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer. ( Arkenau, HT; Burris, HA; Infante, J; Jones, SF; Laille, E; Lemech, C; Liu, L; Patel, M, 2015) |
| " Alternative dosing regimens that do not increase gastric pH at the time of pazopanib dosing should be considered." | 2.78 | Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. ( Botbyl, J; Edenfield, JW; Gibbon, DG; Gregory, C; Lindquist, D; Martin, JC; Stein, MN; Stephenson, JJ; Suttle, AB; Tada, H; Tan, AR, 2013) |
| " Pharmacokinetic sampling for determination of eribulin plasma concentration was performed up to 144 h following administration of eribulin mesylate." | 2.78 | Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. ( Beijnen, JH; Copalu, W; Devriese, LA; Edwards, G; Jenner, A; Marchetti, S; Mergui-Roelvink, M; Peng, F; Reyderman, L; Schellens, JH; Wanders, J, 2013) |
| " The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively." | 2.77 | Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. ( Cohen, EE; Eaton, KN; Fleming, GF; Fox-Kay, K; Gajewski, TF; Hartford, C; House, L; Kocherginsky, M; Maitland, ML; Moshier, K; Nallari, A; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K; Zha, Y, 2012) |
| " Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary." | 2.76 | Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. ( Chen, LC; de Jonge, M; Hamberg, P; Hengelage, T; Li, W; Porro, MG; Sharma, S; van der Biessen, D; Verweij, J; Woo, MM; Zhao, L, 2011) |
| " Segment 2 was designed to evaluate the safety of dasatinib as dosing was increased." | 2.75 | Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. ( Agrawal, S; Blackwood-Chirchir, A; Burris, H; Chiappori, AA; Dhillon, N; Hong, D; Johnson, FM; Kaul, S; Luo, FR; Rosen, L; Sy, O, 2010) |
| " Twelve patients completed the protocol-specified dosing and PK sampling in both cycles 1 and 2." | 2.74 | Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. ( Chatta, G; Chen, E; Cooper, M; Egorin, M; Karol, M; Neuwirth, R; Rader, M; Ramalingam, S; Ramanathan, RK; Riordan, W; Trepicchio, W; Venkatakrishnan, K; von Moltke, L, 2009) |
| "Fourteen patients with advanced solid tumors refractory to standard treatment were enrolled and received motesanib diphosphate 50 mg once daily from day 1 through 15." | 2.73 | Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. ( Chen, L; Heath, EI; Ingram, M; Lorusso, P; Malburg, L; McGreivy, J; Melara, R; Pilat, MJ; Sun, YN; Wiezorek, J; Yan, L, 2008) |
| "Ixabepilone is a good CYP3A4 substrate in vitro; however, in humans, it is likely to be cleared by multiple mechanisms." | 2.73 | The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. ( André, F; Cohen, M; Cömezoglu, SN; Comprelli, A; Goel, S; Goldberg, G; Horwitz, SB; Humphreys, WG; Iacono, L; Jayabalan, D; Ly, VT; Mani, S; McDaid, H; Perrin, L; Xu, C; Zhang, D, 2008) |
| "Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
| " Plasma samples for pharmacokinetic analysis were obtained following the doses on days-6 and 1." | 2.71 | A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. ( DeMario, M; Desai, AA; Fleming, GF; Innocenti, F; Janisch, L; Ramirez, J; Ratain, MJ; Shepard, D, 2004) |
| " However, continuous oral dosing results in progressive decline in plasma drug concentrations, which is associated with relapse and resistance to this retinoid." | 2.67 | Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ( DeGrazia, F; Francis, PA; Huselton, C; Kris, MG; Muindi, JR; Orazem, JP; Rigas, JR; Warrell, RP; Young, CW, 1993) |
| " Bioavailability of ketoconazole was unpredictable." | 2.67 | Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. ( Browne, M; Cotton, D; Gress, J; Hathorn, J; Marshall, D; McKnight, J; Rubin, M; Skelton, J; Thaler, M; Walsh, TJ, 1991) |
| "Amphotericin B may have been more effective than ketoconazole for the treatment of pneumonia." | 2.66 | Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. ( Bodey, GP; Elting, L; Fainstein, V; Keating, M; Maksymiuk, A; McCredie, KB, 1987) |
| " The drug was administered orally in the dosage of 200 mg/m2 of body surface per day for two weeks to cancer patients with oral candidiasis." | 2.65 | Ketoconazole and candidiasis: a controlled study. ( Bartley, DL; Hughes, WT; Patterson, GG; Tufenkeji, H, 1983) |
| "Ketoconazole or miconazole was randomly administered to 42 and 46 neutropenic patients respectively." | 2.65 | Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. ( Cruciani, M; Klastersky, J; Meunier-Carpentier, F, 1983) |
| "Treatment of cancer is increasingly effective but is associated with short and long term side effects." | 2.44 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2007) |
| "Treatment of cancer is increasingly effective but is associated with short and long-term side effects." | 2.42 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2004) |
| "Treatment of cancer is increasingly effective but is associated with short and long-term side effects." | 2.41 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2002) |
| "Patients with cancer complicated by neutropenia." | 2.40 | Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. ( Gøtzsche, PC; Johansen, HK, 1997) |
| "Systemic candidiasis is a disease of increasing incidence and proportions, which appears to be associated with the advances in modern medicine." | 2.38 | Systemic candidiasis. ( Ray, TL, 1989) |
| "Navitoclax is a targeted B-cell lymphoma-2 (Bcl-2) family protein inhibitor." | 1.40 | Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. ( Graham, A; Holen, K; Patnaik, A; Pradhan, R; Salem, AH; Xiong, H; Yang, J, 2014) |
| "When HIV patients with a malignancy need treatment with erlotinib, there is a potential of as-yet-undefined drug-drug interaction." | 1.39 | Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. ( Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R, 2013) |
| "The panel cancer cells used in this study were the following: PC-3, MCF-7 and SKLU-1." | 1.39 | Cytotoxic effect of novel dehydroepiandrosterone derivatives on different cancer cell lines. ( Bratoeff, E; Cabeza, M; Cortés, F; Garrido, M; Gutiérrez, J, 2013) |
| "The anticancer drug docetaxel is extensively metabolized by cytochrome P450 (CYP) 3A isozymes." | 1.34 | Influence of ketoconazole on the fecal and urinary disposition of docetaxel. ( Engels, FK; Loos, WJ; Mathot, RA; van Schaik, RH; Verweij, J, 2007) |
| "Ketoconazole (KTZ) has been used as a second-line agent in hormone-refractory cancer therapy." | 1.32 | Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. ( Anzellotti, A; Rieber, M; Sánchez-Delgado, RA; Strasberg Rieber, M, 2004) |
| " Itraconazole appears to be a safe and effective antimycotic drug in long-term use in neutropenic patients." | 1.28 | Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients. ( König, HJ; Mühldorfer, SM, 1990) |
| " Treatment of invasive aspergillosis required a higher dosage (about 5 mg/kg) and prolonged administration." | 1.28 | Experience with itraconazole in cryptococcosis and aspergillosis. ( Almaviva, M; Cristina, S; De Maria, R; Ferrazzi, P; Fiocchi, R; Langer, M; Negri, C; Scoccia, S; Tortorano, AM; Viviani, MA, 1989) |
| "Invasive fungal infections are becoming increasingly frequent among immunocompromised patients and especially among cancer patients." | 1.27 | Treatment of mycoses in cancer patients. ( Meunier-Carpentier, F, 1983) |
| "Disseminated candidiasis is likely to become an increasing problem in cancer patients." | 1.27 | Candidiasis in cancer patients. ( Bodey, GP, 1984) |
| "Miconazole was most effective against the Candida spp." | 1.26 | In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients. ( Moody, MR; Morris, MJ; Schimpff, SC; Young, VM, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (33.33) | 18.7374 |
| 1990's | 12 (17.39) | 18.2507 |
| 2000's | 15 (21.74) | 29.6817 |
| 2010's | 16 (23.19) | 24.3611 |
| 2020's | 3 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Garrido, M | 1 |
| Cabeza, M | 2 |
| Cortés, F | 1 |
| Gutiérrez, J | 1 |
| Bratoeff, E | 2 |
| Silva-Ortiz, AV | 1 |
| Ramírez-Apan, T | 1 |
| Heuze, Y | 1 |
| Sánchez, A | 1 |
| Soriano, J | 1 |
| Qiu, Q | 1 |
| Shi, W | 1 |
| Li, Z | 1 |
| Zhang, B | 1 |
| Pan, M | 1 |
| Cui, J | 1 |
| Dai, Y | 1 |
| Huang, W | 1 |
| Qian, H | 1 |
| Cheong, EJY | 1 |
| Ng, DZW | 1 |
| Chin, SY | 1 |
| Wang, Z | 1 |
| Chan, ECY | 1 |
| Amini, A | 1 |
| Mesbah, G | 1 |
| Tash Shamsabadi, F | 1 |
| Zeyghami, MA | 1 |
| Safdari, Y | 1 |
| da Silva Dos Reis Condé, CA | 1 |
| de Andrade Querino, AL | 1 |
| Silva, H | 1 |
| Navarro, M | 1 |
| Gupta, N | 1 |
| Hanley, MJ | 1 |
| Venkatakrishnan, K | 2 |
| Bessudo, A | 1 |
| Rasco, DW | 1 |
| Sharma, S | 3 |
| O'Neil, BH | 1 |
| Wang, B | 1 |
| Liu, G | 1 |
| Ke, A | 1 |
| Patel, C | 1 |
| Rowland Yeo, K | 1 |
| Xia, C | 1 |
| Zhang, X | 1 |
| Esseltine, DL | 1 |
| Nemunaitis, J | 1 |
| Tan, AR | 1 |
| Gibbon, DG | 1 |
| Stein, MN | 1 |
| Lindquist, D | 1 |
| Edenfield, JW | 1 |
| Martin, JC | 1 |
| Gregory, C | 1 |
| Suttle, AB | 1 |
| Tada, H | 1 |
| Botbyl, J | 1 |
| Stephenson, JJ | 1 |
| Pillai, VC | 1 |
| Venkataramanan, R | 1 |
| Parise, RA | 1 |
| Christner, SM | 1 |
| Gramignoli, R | 1 |
| Strom, SC | 1 |
| Rudek, MA | 1 |
| Beumer, JH | 1 |
| Salem, AH | 1 |
| Yang, J | 1 |
| Graham, A | 1 |
| Patnaik, A | 1 |
| Holen, K | 1 |
| Pradhan, R | 1 |
| Xiong, H | 1 |
| Machiels, JP | 1 |
| Staddon, A | 1 |
| Herremans, C | 1 |
| Keung, C | 1 |
| Bernard, A | 1 |
| Phelps, C | 1 |
| Khokhar, NZ | 1 |
| Knoblauch, R | 1 |
| Parekh, TV | 1 |
| Dirix, L | 1 |
| Sarantopoulos, J | 1 |
| Mita, AC | 1 |
| Wade, JL | 1 |
| Morris, JC | 1 |
| Rixe, O | 1 |
| Mita, MM | 1 |
| Dedieu, JF | 1 |
| Wack, C | 1 |
| Kassalow, L | 1 |
| Lockhart, AC | 1 |
| Laille, E | 1 |
| Patel, M | 1 |
| Jones, SF | 1 |
| Burris, HA | 1 |
| Infante, J | 1 |
| Lemech, C | 1 |
| Liu, L | 1 |
| Arkenau, HT | 1 |
| Einolf, HJ | 1 |
| Zhou, J | 1 |
| Won, C | 1 |
| Wang, L | 1 |
| Rebello, S | 1 |
| Lorusso, P | 1 |
| Heath, EI | 1 |
| McGreivy, J | 1 |
| Sun, YN | 1 |
| Melara, R | 1 |
| Yan, L | 1 |
| Malburg, L | 1 |
| Ingram, M | 1 |
| Wiezorek, J | 1 |
| Chen, L | 1 |
| Pilat, MJ | 1 |
| Johnson, FM | 1 |
| Agrawal, S | 1 |
| Burris, H | 1 |
| Rosen, L | 1 |
| Dhillon, N | 1 |
| Hong, D | 1 |
| Blackwood-Chirchir, A | 1 |
| Luo, FR | 1 |
| Sy, O | 1 |
| Kaul, S | 1 |
| Chiappori, AA | 1 |
| Rader, M | 1 |
| Ramanathan, RK | 1 |
| Ramalingam, S | 1 |
| Chen, E | 2 |
| Riordan, W | 1 |
| Trepicchio, W | 1 |
| Cooper, M | 1 |
| Karol, M | 1 |
| von Moltke, L | 1 |
| Neuwirth, R | 1 |
| Egorin, M | 1 |
| Chatta, G | 1 |
| Hamberg, P | 1 |
| Woo, MM | 1 |
| Chen, LC | 1 |
| Verweij, J | 3 |
| Porro, MG | 1 |
| Zhao, L | 1 |
| Li, W | 1 |
| van der Biessen, D | 1 |
| Hengelage, T | 1 |
| de Jonge, M | 1 |
| Devriese, LA | 1 |
| Mergui-Roelvink, M | 1 |
| Wanders, J | 1 |
| Jenner, A | 1 |
| Edwards, G | 1 |
| Reyderman, L | 1 |
| Copalu, W | 1 |
| Peng, F | 1 |
| Marchetti, S | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Cohen, EE | 1 |
| Wu, K | 1 |
| Hartford, C | 1 |
| Kocherginsky, M | 1 |
| Eaton, KN | 1 |
| Zha, Y | 1 |
| Nallari, A | 1 |
| Maitland, ML | 1 |
| Fox-Kay, K | 1 |
| Moshier, K | 1 |
| House, L | 1 |
| Ramirez, J | 2 |
| Undevia, SD | 1 |
| Fleming, GF | 2 |
| Gajewski, TF | 1 |
| Ratain, MJ | 2 |
| Lassen, U | 1 |
| Miller, WH | 1 |
| Hotte, S | 1 |
| Evans, TR | 1 |
| Kollmansberger, C | 1 |
| Adamson, D | 1 |
| Nielsen, DL | 1 |
| Spicer, J | 1 |
| Meyer, T | 1 |
| Brown, K | 1 |
| Rafi, R | 1 |
| Sawyer, MB | 1 |
| Baldwin, A | 1 |
| Huang, Z | 1 |
| Jounaidi, Y | 1 |
| Waxman, DJ | 1 |
| Clarkson, JE | 3 |
| Worthington, HV | 3 |
| Eden, OB | 3 |
| Desai, AA | 1 |
| Innocenti, F | 1 |
| Janisch, L | 1 |
| DeMario, M | 1 |
| Shepard, D | 1 |
| Ozçelik, B | 1 |
| Citak, S | 1 |
| Cesur, S | 1 |
| Abbasoğlu, U | 1 |
| Içli, F | 1 |
| Strasberg Rieber, M | 1 |
| Anzellotti, A | 1 |
| Sánchez-Delgado, RA | 1 |
| Rieber, M | 1 |
| Engels, FK | 2 |
| Mathot, RA | 2 |
| Loos, WJ | 2 |
| van Schaik, RH | 2 |
| Yong, WP | 1 |
| Wang, LZ | 1 |
| Tham, LS | 1 |
| Wong, CI | 1 |
| Lee, SC | 1 |
| Soo, R | 1 |
| Sukri, N | 1 |
| Lee, HS | 1 |
| Goh, BC | 1 |
| Goel, S | 1 |
| Cohen, M | 1 |
| Cömezoglu, SN | 1 |
| Perrin, L | 1 |
| André, F | 1 |
| Jayabalan, D | 1 |
| Iacono, L | 1 |
| Comprelli, A | 1 |
| Ly, VT | 1 |
| Zhang, D | 1 |
| Xu, C | 1 |
| Humphreys, WG | 1 |
| McDaid, H | 1 |
| Goldberg, G | 1 |
| Horwitz, SB | 1 |
| Mani, S | 1 |
| Sheklakov, ND | 1 |
| Rukavishnikova, VM | 1 |
| Bodey, GP | 4 |
| Maksymiuk, AW | 2 |
| Thongprasert, S | 1 |
| Hopfer, R | 1 |
| Luna, M | 1 |
| Fainstein, V | 2 |
| Quintiliani, R | 1 |
| Owens, NJ | 1 |
| Quercia, RA | 1 |
| Klimek, JJ | 1 |
| Nightingale, CH | 1 |
| Moody, MR | 1 |
| Young, VM | 1 |
| Morris, MJ | 1 |
| Schimpff, SC | 1 |
| Chretien, JH | 1 |
| Garagusi, VF | 1 |
| Young, LS | 1 |
| Levine, HB | 1 |
| Meunier-Carpentier, F | 4 |
| Cruciani, M | 1 |
| Klastersky, J | 1 |
| Hughes, WT | 1 |
| Bartley, DL | 1 |
| Patterson, GG | 1 |
| Tufenkeji, H | 1 |
| Lee, JS | 1 |
| Newman, RA | 1 |
| Lippman, SM | 1 |
| Fossella, FV | 1 |
| Calayag, M | 1 |
| Raber, MN | 1 |
| Krakoff, IH | 1 |
| Hong, WK | 1 |
| Muindi, JR | 2 |
| Young, CW | 2 |
| Warrell, RP | 2 |
| Rigas, JR | 1 |
| Francis, PA | 1 |
| Kris, MG | 1 |
| Huselton, C | 1 |
| DeGrazia, F | 1 |
| Orazem, JP | 1 |
| Gøtzsche, PC | 1 |
| Johansen, HK | 1 |
| Stewart, DJ | 2 |
| Cripps, MC | 1 |
| Goel, R | 1 |
| Dahrouge, S | 1 |
| Yau, J | 1 |
| Tomiak, E | 1 |
| Huan, S | 1 |
| Soltys, K | 1 |
| Prosser, A | 1 |
| Davies, RA | 1 |
| Krcmery, V | 3 |
| Oravcova, E | 1 |
| Spanik, S | 1 |
| Mrazova-Studena, M | 1 |
| Trupl, J | 1 |
| Kunova, A | 1 |
| Stopkova-Grey, K | 1 |
| Kukuckova, E | 1 |
| Krupova, I | 1 |
| Demitrovicova, A | 1 |
| Kralovicova, K | 1 |
| Sejnova, D | 2 |
| Pichnova, E | 2 |
| Krupova, Y | 1 |
| Dzatkova, J | 1 |
| Kaiserova, E | 1 |
| Kiskova, M | 1 |
| Babela, R | 1 |
| Mateicka, F | 1 |
| Sabo, A | 1 |
| Jurga, L | 1 |
| Sulcova, M | 1 |
| Méresse, V | 1 |
| Hartmann, O | 1 |
| Vassal, G | 1 |
| Benhamou, E | 1 |
| Valteau-Couanet, D | 1 |
| Brugieres, L | 1 |
| Lemerle, J | 1 |
| Braunschweiger, PG | 1 |
| Jones, SA | 1 |
| Johnson, CS | 1 |
| Furmanski, P | 1 |
| Caselli, D | 1 |
| Aricò, M | 1 |
| Michelone, G | 1 |
| Cavanna, C | 1 |
| Nespoli, L | 1 |
| Burgio, GR | 1 |
| Walsh, TJ | 1 |
| Rubin, M | 1 |
| Hathorn, J | 1 |
| Gress, J | 1 |
| Thaler, M | 1 |
| Skelton, J | 1 |
| McKnight, J | 1 |
| Browne, M | 1 |
| Marshall, D | 1 |
| Cotton, D | 1 |
| Mühldorfer, SM | 1 |
| König, HJ | 2 |
| Viviani, MA | 1 |
| Tortorano, AM | 1 |
| Langer, M | 1 |
| Almaviva, M | 1 |
| Negri, C | 1 |
| Cristina, S | 1 |
| Scoccia, S | 1 |
| De Maria, R | 1 |
| Fiocchi, R | 1 |
| Ferrazzi, P | 1 |
| Evans, WK | 1 |
| Ray, TL | 1 |
| Van Wauwe, JP | 1 |
| Janssen, PA | 1 |
| Georgiou, A | 1 |
| Kraft, P | 1 |
| Mayer, U | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Oyamada, H | 1 |
| Tainaka, K | 1 |
| Morita, Y | 1 |
| Kogawa, T | 1 |
| Sugino, S | 1 |
| Kondo, M | 1 |
| Rochlitz, CF | 1 |
| Damon, LE | 1 |
| Russi, MB | 1 |
| Geddes, A | 1 |
| Cadman, EC | 1 |
| Hansen, RM | 1 |
| Reinerio, N | 1 |
| Sohnle, PG | 1 |
| Abrams, RA | 1 |
| Ritch, PS | 1 |
| Libnoch, JA | 1 |
| Anderson, T | 1 |
| Elting, L | 1 |
| Maksymiuk, A | 1 |
| Keating, M | 1 |
| McCredie, KB | 1 |
| Scrimgeour, E | 1 |
| Anderson, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma[NCT01454076] | Phase 1 | 112 participants (Actual) | Interventional | 2011-11-10 | Completed | ||
| An Open-Label Study to Evaluate the Effects of Ketoconazole and the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Repeat Doses of Pazopanib in Subjects With Solid Tumor Malignancies[NCT01205230] | Phase 4 | 34 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01267084] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01273480] | Phase 1 | 12 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Cytochrome P450 Inhibition With Ketoconazole to Decrease Dosage and Costs of Dasatinib for Chronic Myelogenous Leukemia[NCT05638763] | Phase 2 | 15 participants (Anticipated) | Interventional | 2024-11-30 | Recruiting | ||
| Effect of Ketoconazole Administration on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors[NCT00129207] | Phase 1 | 0 participants | Interventional | Completed | |||
| A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors.[NCT00503451] | Phase 1 | 14 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone In Patients With Advanced Cancer[NCT00096317] | Phase 1 | 29 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram*hour per milliliter (ng*hr/mL)] (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 551.985 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1148.778 |
| Arm 2: Ixazomib 4 mg Capsule A | 1284.079 |
| Arm 2: Ixazomib 4 mg Capsule B | 1334.659 |
| Arm 3: Ixazomib 4 mg Fasted | 1465.979 |
| Arm 3: Ixazomib 4 mg Fed | 998.698 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 231.527 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 613.112 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hours[hrs])post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 38.975 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 39.250 |
| Arm 2: Ixazomib 4 mg Capsule A | 61.866 |
| Arm 2: Ixazomib 4 mg Capsule B | 71.949 |
| Arm 3: Ixazomib 4 mg Fasted | 77.001 |
| Arm 3: Ixazomib 4 mg Fed | 22.752 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 25.706 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 37.245 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) |
|---|---|
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | hours (Median) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 1.090 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1.500 |
| Arm 2: Ixazomib 4 mg Capsule A | 1.290 |
| Arm 2: Ixazomib 4 mg Capsule B | 1.250 |
| Arm 3: Ixazomib 4 mg Fasted | 1.020 |
| Arm 3: Ixazomib 4 mg Fed | 4.000 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 1.450 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45)
| Intervention | participants (Number) | |
|---|---|---|
| TEAEs | SAEs | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 29 | 12 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 20 | 5 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 24 | 12 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 18 | 3 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 21 | 10 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) | ||
|---|---|---|---|
| Blood and lymphatic system disorders | Investigations | Metabolism and nutrition disorders | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 11 | 10 | 22 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 7 | 5 | 12 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 9 | 11 | 13 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 2 | 4 | 6 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 | 5 | 6 |
Best overall response for a participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (<) 10 millimeter [mm]). No new lesions. Partial response (PR) was defined as greater than or equal to (>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, Progressive Disease (PD). An increase of >=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest) represents PD. (NCT01454076)
Timeframe: Baseline up to end of treatment (approximately 1.9 years)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| CR | PR | SD | PD | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 | 0 | 63 | 38 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 | 0 | 50 | 50 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 | 6 | 35 | 59 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 | 0 | 53 | 47 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 | 1 | 53 | 47 |
The following were considered DLTs only while participants were receiving pazopanib co-administered with either ketoconazole or esomeprazole: Grade 4 hematologic toxicities, excluding lymphopenia; and Grade 3/4 non-hematologic toxicities, excluding alopecia and nausea/vomiting/diarrhea for which adequate supportive therapy had not been instituted. Toxicities observed once co-administration of pazopanib with ketoconazole or esomeprazole was complete (after Day 5 of Period 2) could also be considered DLTs if judged to be relevant by the investigator and the GlaxoSmithKline Medical Monitor. (NCT01205230)
Timeframe: From Baseline (Day 1) to a maximum of 4 weeks after the last dose of study drug was administered (on Study Day 12)
| Intervention | participants (Number) |
|---|---|
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 2 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 0 |
Pazopanib plasma concentration-time data were analyzed by non-compartmental methods with WinNonlin. Calculations were based on the actual sampling times. From the plasma concentration-time data, the PK parameter C24 was determined. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained 24 hours after administration of pazopanib.
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Pazopanib 400 mg QD | 26.9 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 48.7 |
| Pazopanib 800 mg QD | 27.2 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 17.3 |
Blood samples for PK analysis of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. The concentration-time curve is the result of time points of blood sampling and its measured concentration of pazopanib in the plasma. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Pazopanib 400 mg QD | 40.7 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 59.2 |
| Pazopanib 800 mg QD | 48.9 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 28.4 |
Blood samples for pharmacokinetic (PK) analysis of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter AUC(0-24) was determined by standard non-compartmental analysis using WinNonlin. Plasma AUC(0-24) is a measure of the amount of drug a participant has been exposed to in 24 hours. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | Hour*micrograms/milliliters (hr*mcg/mL) (Geometric Mean) |
|---|---|
| Pazopanib 400 mg QD | 786 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 1300 |
| Pazopanib 800 mg QD | 848 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 512 |
Blood samples for PK analysis of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Nominal data collection time points (TPs) were defined in the protocol; however, the actual data collection TP often differed slightly from the nominal TP for various reasons. This leads to medians and ranges that don't coincide with planned nominal data collection TPs. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | hours (hr) (Median) |
|---|---|
| Pazopanib 400 mg QD | 3.48 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 3.48 |
| Pazopanib 800 mg QD | 3 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 3.9 |
AEs were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0. Grades range from 0 (no toxicity) to 4 (life-threatening or disabling). A Grade 3 AE is severe; defined as considerable interference with the participant's daily activities, medical intervention/therapy required, and hospitalization possible. A Grade 4 AE is life-threatening; defined as extreme limitation in activity, significant medical intervention/therapy required, and hospitalization probable. (NCT01205230)
Timeframe: From Baseline (Day 1) to a maximum of 4 weeks after the last dose of study drug was administered (on Study Day 12)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Hypertension | Hypokalemia | Hypophosphatemia | Lymphopenia | |
| Pazopanib 400 mg QD | 1 | 0 | 0 | 0 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 2 | 1 | 1 | 1 |
| Pazopanib 800 mg QD | 0 | 0 | 0 | 0 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 2 | 0 | 0 | 0 |
Blood samples for PK analysis of the metabolites of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter AUC(0-24) was determined by standard non-compartmental analysis using WinNonlin. Plasma AUC(0-24) is a measure of the amount of drug a participant has been exposed to in 24 hours. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | hr*mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| GSK1268992, n=21, 16, 12, 12 | GSK1268997, n=20, 13, 12, 12 | GSK1071306, n=21, 15, 12, 12 | |
| Pazopanib 400 mg QD | 30.3 | 17.4 | 7.61 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 30.3 | 6.67 | 4.26 |
| Pazopanib 800 mg QD | 35.5 | 21.6 | 11.7 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 20.8 | 11.2 | 8.14 |
Blood samples for PK analysis of the metabolites of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. The concentration-time curve is the result of time points of blood sampling and its measured concentration of pazopanib in the plasma. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| GSK1268992 | GSK1268997 | GSK1071306 | |
| Pazopanib 400 mg QD | 1.55 | 1.02 | 0.39 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 1.52 | 0.31 | 0.22 |
| Pazopanib 800 mg QD | 1.95 | 1.65 | 0.61 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 1.13 | 0.84 | 0.42 |
Blood samples for the determination of plasma ketoconazole concentrations were collected before (pre-dose [within 60 minutes prior to pazopanib administration]) and after the final pazopanib and ketoconazole dose (fifth dose) during Period 2 at the indicated time points, relative to pazopanib administration (at 1 and 2 hours after pazopanib administration). Blood samples were obtained via peripheral intravenous cannula or central line. Concentrations of ketoconazole were determined in plasma samples using the currently approved analytical methodology. (NCT01205230)
Timeframe: Day 5 of Period 2 (combination therapy). Blood samples were collected within 60 minutes prior to pazopanib administration and 1 and 2 hours after pazopanib administration.
| Intervention | mcg/mL (Mean) | ||
|---|---|---|---|
| Pre-dose | 1 hr | 2 hr | |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 0.53 | 4.21 | 4.82 |
Blood samples for PK analysis of pazopanib were obtained at pre-dose (within 60 minutes prior to pazopanib administration) and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Nominal data collection time points (TPs) were defined in the protocol; however, the actual data collection TP often differed slightly from the nominal TP for various reasons. This leads to medians and ranges that don't coincide with planned nominal data collection TPs. (NCT01205230)
Timeframe: Day 7 of Period 1 (monotherapy) and Day 5 (Study Day 12) of Period 2 (combination therapy). Blood samples were obtained within 60 minutes prior to pazopanib administration and at 1, 2, 3, 4, 6, 8, and 24 hours after pazopanib administration.
| Intervention | hr (Median) | ||
|---|---|---|---|
| GSK1268992 | GSK1268997 | GSK1071306 | |
| Pazopanib 400 mg QD | 4 | 3.02 | 3.12 |
| Pazopanib 400 mg QD + Ketoconazole 400 mg QD | 24 | 13.4 | 24.1 |
| Pazopanib 800 mg QD | 3 | 2.2 | 3.9 |
| Pazopanib 800 mg QD + Esomeprazole 40 mg QD | 3 | 2.4 | 6 |
10 reviews available for ketoconazole and Benign Neoplasms
| Article | Year |
|---|---|
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2004 |
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2007 |
[Imidazole preparations in mycology].
Topics: Animals; Antifungal Agents; Candidiasis; Clotrimazole; Coccidioidomycosis; Cryptococcosis; Dermatomy | 1984 |
Current management of fungal enteritis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Diarrhea; Enteritis; Histoplasmosis; Humans; Imidazo | 1982 |
Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections.
Topics: Administration, Oral; Administration, Topical; Amphotericin B; Antifungal Agents; Candidiasis; Clini | 1984 |
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Miconazole; Myco | 1997 |
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2002 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chem | 1989 |
Systemic candidiasis.
Topics: Amphotericin B; Candidiasis; Flucytosine; Humans; Immune Tolerance; Ketoconazole; Neoplasms; Opportu | 1989 |
Is there a case for P-450 inhibitors in cancer treatment?
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzym | 1989 |
31 trials available for ketoconazole and Benign Neoplasms
| Article | Year |
|---|---|
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarit | 2018 |
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CY | 2013 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Area Under Curve; Cisplatin | 2014 |
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome | 2015 |
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Topics: Adult; Biphenyl Compounds; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Induc | 2017 |
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Topics: Aged; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administra | 2008 |
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3 | 2010 |
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Topics: Antifungal Agents; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cross-Over St | 2009 |
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Topics: Adult; Aged; Antifungal Agents; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Topics: Administration, Oral; Aged; Antifungal Agents; Dose-Response Relationship, Drug; Female; Follow-Up S | 2013 |
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2012 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Inter | 2013 |
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Capsules; Chemistry, Pharmaceutical; Cytochro | 2004 |
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyto | 2006 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Computational Biology; Cytochrome P-450 CYP3A | 2008 |
Treatment and prevention of oropharyngeal candidiasis.
Topics: Adolescent; Adult; Aged; Aspergillosis; Candidiasis; Child; Child, Preschool; Clinical Trials as Top | 1984 |
Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients.
Topics: Agranulocytosis; Antifungal Agents; Candidiasis; Drug Combinations; Female; Humans; Imidazoles; Keto | 1983 |
Ketoconazole and candidiasis: a controlled study.
Topics: Adolescent; Antifungal Agents; Candidiasis, Oral; Child; Clinical Trials as Topic; Double-Blind Meth | 1983 |
Prophylaxis of fungal infections in neutropenic cancer patients.
Topics: Agranulocytosis; Amphotericin B; Aspergillosis; Candidiasis; Clinical Trials as Topic; Humans; Ketoc | 1983 |
Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections.
Topics: Administration, Oral; Administration, Topical; Amphotericin B; Antifungal Agents; Candidiasis; Clini | 1984 |
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.
Topics: Adult; Aged; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Tretinoin | 1995 |
Clinical pharmacology of all-trans retinoic acid.
Topics: Antineoplastic Agents; Drug Administration Schedule; Half-Life; Humans; Ketoconazole; Neoplasms; Ste | 1994 |
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug | 1993 |
Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Child; Child, Preschool; Feces; Female; Humans; Infan | 1990 |
Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study.
Topics: Adult; Agranulocytosis; Amphotericin B; Fever; Humans; Immune Tolerance; Ketoconazole; Mycoses; Neop | 1991 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chem | 1989 |
Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study.
Topics: Candidiasis; Candidiasis, Oral; Clinical Trials as Topic; Double-Blind Method; Humans; Immunosuppres | 1987 |
Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Female; Humans; Ketoconazole; Male; Middle Aged; Mycoses; N | 1987 |
Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy. An open randomized comparison between 200 mg/d and 400 mg/d doses.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Immunosuppressive Agents; Ketoconaz | 1985 |
30 other studies available for ketoconazole and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Cytotoxic effect of novel dehydroepiandrosterone derivatives on different cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Humans; Neoplas | 2013 |
Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
Topics: 5-alpha Reductase Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2015 |
Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-4 | 2017 |
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Bi | 2022 |
Tumour induction in BALB/c mice for imaging studies: An improved protocol.
Topics: Animals; Cyclophosphamide; Cyclosporine; Humans; Ketoconazole; Mice; Mice, Inbred BALB C; Mice, Nude | 2023 |
Silver(I) complexes containing N-heterocyclic carbene azole drugs: Synthesis, characterization, cytotoxic activity, and their BSA interactions.
Topics: Animals; Antineoplastic Agents; Azoles; Clotrimazole; Coordination Complexes; Humans; Ketoconazole; | 2023 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; | 2013 |
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Cytochrome P-450 CYP3A Inh | 2014 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alk | 2003 |
In vitro susceptibility of Candida species isolated from cancer patients to some antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Candida; Disease Susceptibility; Fluconazole; Flucytosine; Humans | 2004 |
Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous | 2004 |
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Topics: Administration, Oral; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2007 |
Candidiasis in cancer patients.
Topics: Amphotericin B; Antibodies, Fungal; Candidiasis; Cephalosporins; Humans; Ketoconazole; Leukemia; Mic | 1984 |
Systemic candidiasis in cancer patients.
Topics: Acute Disease; Amphotericin B; Bacterial Infections; Bacteriological Techniques; Candida; Candidiasi | 1984 |
In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients.
Topics: Antifungal Agents; Candida; Drug Synergism; Humans; Imidazoles; Ketoconazole; Miconazole; Microbial | 1980 |
The outlook for antifungal prophylaxis in the compromised host.
Topics: Candidiasis; Humans; Imidazoles; Immunity; Ketoconazole; Miconazole; Mycoses; Neoplasms; Nystatin; P | 1982 |
Pharmacokinetics of ketoconazole in patients with neoplastic diseases.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Female; Half-Life; Humans; Imidazoles; Ketoconazole; Kin | 1982 |
Treatment of mycoses in cancer patients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Candidiasis, Oral; Drug Therapy, Comb | 1983 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal | 1997 |
Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Agents; Cross Infection; Drug Resistance, Microbia | 1998 |
Breakthrough Candida tropicalis fungemia during ketoconazole prophylaxis in cancer patients.
Topics: Adult; Antibiotic Prophylaxis; Antifungal Agents; Candida; Candidiasis; Child; Female; Fungemia; Hum | 1999 |
Prospective study on fungemia in children with cancer: analysis of 35 cases and comparison with 130 fungemias in adults.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antifungal Agents; Candida albicans; Candidiasis; Child; | 2000 |
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Hepatic Veno-Occ | 1992 |
Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Screening Assays, Antit | 1991 |
Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients.
Topics: Adult; Aged; Antifungal Agents; Female; Humans; Immune Tolerance; Itraconazole; Ketoconazole; Male; | 1990 |
Experience with itraconazole in cryptococcosis and aspergillosis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Cryptoc | 1989 |
[Prevention of fungal infections with ketoconazole in cancer patients receiving cytostatic therapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Ketoconazole; Mal | 1988 |
Esophageal candidiasis.
Topics: Amphotericin B; Autoimmune Diseases; Candidiasis; Esophageal Diseases; Esophagoscopy; Female; Humans | 1988 |
Cytotoxicity of ketoconazole in malignant cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Humans; | 1988 |